[Skip to Navigation]
Sign In
Invited Commentary
January 6, 2022

When Radiotherapy and Immunotherapy Dance—Who Leads So as Not to Step on Toes?

Author Affiliations
  • 1Memorial Sloan Kettering Cancer Center, New York, New York
  • 2University of Colorado, Aurora
JAMA Oncol. 2022;8(2):240-241. doi:10.1001/jamaoncol.2021.6436

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several cancers, significantly increasing survival in advanced disease. A substantial proportion of these patients have received radiotherapy (RT) prior to or after ICI treatment. We have aggressively moved toward strategies combining RT and immunotherapy concurrently or sequentially in oligometastatic disease. Importantly, this strategy has gravitated to earlier stages of disease, with some outstanding successes.1 What have we learned about the toxicity implications associated with this combination, and how might we mitigate harm to the patient?

Add or change institution